Asarfi Hospital Ltd

Asarfi Hospital Ltd has submitted its Annual Report for the Financial Year 2025-26, along with the Notice for the upcoming Annual General Meeting (AGM). This filing complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Annual Report, which includes details such as the Director's Report, financial statements, and corporate governance information, is also accessible on the company's website via a provided link. The company has also shared its vision, mission, and core values, emphasizing patient care and technological advancement.

Asarfi Hospital Ltd announced the appointment of M/s Ashutosh Kumar Sinha & Co as its Cost Auditor for the Financial Year 2026-27. The decision was approved by the Board of Directors on August 25, 2026, following a recommendation from the Audit Committee. This appointment is in compliance with Section 148 of the Companies Act, 2013. The company also acknowledged a delay in this regulatory filing due to an inadvertent omission and expressed regret, stating that steps are being taken to improve internal compliance mechanisms for future timely disclosures.

Asarfi Hospital Limited held a Board of Directors meeting on August 25, 2026. Key decisions included approving the Directors' Report for the year ended March 31, 2026, and the re-appointment of Director Mr. Gopal Singh. The Board also decided to convene the 21st Annual General Meeting (AGM) on September 18, 2026, setting September 5-18, 2026, for book closure and September 11, 2026, as the e-voting cut-off date. Furthermore, the company approved its migration from the BSE SME Platform to the BSE Main Board and proposed listing on NSE, subject to shareholder and regulatory approvals. The appointment of a Cost Auditor for FY 2026-27 and an authorized signatory for bidding processes were also approved.

Asarfi Hospital Ltd has scheduled its 4th Board of Directors meeting for FY 2026-27 on August 25, 2026. The meeting will address key agenda items including the approval of the Directors' Report for FY 2025-26, the re-appointment of retiring director Mr. Gopal Singh, and the fixing of the date for the 21st Annual General Meeting (AGM) on September 18, 2026. Additionally, the board will consider appointing a Cost Auditor for FY 2026-27 and discuss a significant proposal for migration from the BSE SME Platform to the BSE Main Board and listing on the NSE. The meeting will also cover the approval of book closure for the AGM and the appointment of a scrutinizer for e-voting.

Asarfi Hospital Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a significant 33% year-on-year increase in revenue, reaching ₹4,734 Lakhs. This growth was driven by better realizations, improved Average Revenue Per Bed Occupancy Day (ARPOB), and an enhanced case mix across its super-specialty and oncology units. EBITDA margin stood at 20%, and PAT margin was 9%. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 07, 2026.

Asarfi Hospital Limited announced that its Board of Directors, in a meeting held on August 7, 2026, has considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company submitted the results along with the limited review reports from its statutory auditors, R K Thakkar & Co. The board meeting commenced at 3:00 PM and concluded at 6:00 PM. The filing also included the standalone unaudited balance sheet as of June 30, 2026.

Asarfi Hospital Limited announced that its Board of Directors has approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and approved by the Board on August 7, 2026. The company's statutory auditors have issued a Limited Review Report on these results. The financial statements were prepared in accordance with Indian Accounting Standards. The company operates in a single reportable segment: Hospital.

Asarfi Hospital Ltd has announced that its Board of Directors will convene on August 7, 2026, at 3:00 PM IST. The primary agenda item is the consideration and approval of the Unaudited Financial Results for the quarter ended June 30, 2026. The meeting will also involve reviewing the Limited Review Report from the statutory auditors, M/s R. K. Thakkar & Co. Other standard board meeting procedures, such as confirming previous minutes and addressing any other business with the chair's permission, will also be conducted.

Asarfi Hospital Limited's management participated in an Analyst/Investor Webinar on July 24, 2026. They provided an overview of business operations, financial performance, and strategic initiatives. Key highlights included consistent year-on-year revenue and PAT growth, a reiterated revenue target of ₹400 crore by FY2028, and updates on the expansion of oncology and cardiology services. The company is bidding for a 100-seat Medical College under PPP, establishing nursing colleges, and planning a Bone Marrow Transplant facility. Preparations for migration to the Main Board are underway, and an acquisition of a 70-bed hospital is being evaluated. No Unpublished Price Sensitive Information was disclosed.

Asarfi Hospital Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, effective July 1, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The date of the board meeting to consider these financial results will be communicated separately.